中芯(00981.HK)曾續跌半成失19元 遭美列實體名單不利10納米或以下產能研發
中芯(00981.HK)指遭美國列入實體名單對公司10納米及以下先進研發產能有重大不利影響。該股延續上周五弱勢,今早曾挫4.8%低見18.9元,創逾兩個月低,現造19.34元,續跌2.6%,成交3,589萬股;中芯A股跌2.5%曾低見52.8元人民幣。
中芯公布,關注到美國商務部上周五(18日)以保護美國國家安全和外交利益為由,將公司及部分附屬公司和聯營公司列入實體名單。集團經初步評估,上述事項對公司短期營運及財務狀況無重大不利影響,但對10納米及以下先進研發產能有重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.